Who is sponsoring NCT00455858?

NCT00455858 is sponsored by Novo Nordisk A/S.

What condition does NCT00455858 study?

NCT00455858 studies Diabetes, Diabetes Mellitus, Type 2.

What drugs are being tested in NCT00455858?

Interventions: insulin detemir.

What is the status of NCT00455858?

NCT00455858 is currently COMPLETED.

Last reviewed 2024-01-31 · How we verify

A 20-week, Multi-centre, Open-labelled, Non-comparative Evaluation of the Safety and Efficacy of Insulin Detemir in Combination With Oral Anti-diabetic Drug(s), in Subjects With Type 2 Diabetes Mellitus Who Were Inadequately Controlled on Current Therapy in Korea

NCT00455858 Phase 4 COMPLETED Results posted

This trial is conducted in Asia. This trial aims for evaluating the glycaemic control, measured as glycosylated haemoglobin (Hb1Ac), of once daily insulin detemir as an add-on to oral antidiabetic drug (OAD) in subjects with type 2 diabetes mellitus in Korea.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 4
Status	COMPLETED
Enrolment	87
Start date	2007-11
Completion	2008-10

Conditions

Diabetes
Diabetes Mellitus, Type 2

Interventions

insulin detemir

Primary outcomes

Change in Glycosylated Haemoglobin A1c (HbA1c) at Week 20 — week 0, week 20
Change in Glycosylated Haemoglobin A1c (HbA1c) from baseline to week 20

Countries

South Korea